Mixed bacterial-fungal infection following total hip arthroplasty: A case report.
Arthroplasty
Candida albicans
Hip
Prosthesis-related infections
Staphylococcus hominis
Journal
Chinese journal of traumatology = Zhonghua chuang shang za zhi
ISSN: 1008-1275
Titre abrégé: Chin J Traumatol
Pays: China
ID NLM: 100886162
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
received:
21
01
2021
revised:
27
05
2021
accepted:
15
06
2021
pubmed:
8
8
2021
medline:
27
1
2022
entrez:
7
8
2021
Statut:
ppublish
Résumé
Prosthetic infection is one of the severe postoperative complications of arthroplasty. Mixed bacterial-fungal prosthetic infection is rare but can be disastrous. This case was a 76-year-old female suffered from prosthetic infection following total hip replacement due to femoral neck fracture and underwent multiple debridements. The culture of periprosthetic tissue was bacteriologically sterile following the first debridement, while the Staphylococcus hominis was identified in the second debridement in the previous hospitalization where fungal infection had not been considered. Thus the pathogen spectrum of anti-infection therapy failed to contain fungus. Ultimately, the culture result of our sampled periprosthetic tissue during the third debridement was Candida albicans without bacterium in our hospital. The fungal prosthetic infection was successfully treated by a two-stage revision with antifungal drugs. Accurate diagnosis and standardized treatment is the key to the therapy of infection after hip arthroplasty, especially for mixed bacterial-fungal prosthetic infection.
Identifiants
pubmed: 34362649
pii: S1008-1275(21)00122-X
doi: 10.1016/j.cjtee.2021.07.010
pmc: PMC8787236
pii:
doi:
Substances chimiques
Anti-Bacterial Agents
0
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
32-36Informations de copyright
Copyright © 2021 Chinese Medical Association. Production and hosting by Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors have no personal, financial, or institutional interest in any of the drugs, materials, or devices described in this article.
Références
Clin Infect Dis. 2009 Mar 1;48(5):503-35
pubmed: 19191635
J Bacteriol. 2001 Sep;183(18):5385-94
pubmed: 11514524
J Arthroplasty. 2019 Feb;34(2S):S387-S391
pubmed: 30343967
BMJ Case Rep. 2012 Sep 24;2012:
pubmed: 23008369
J Arthroplasty. 2014 Feb;29(2 Suppl):112-4
pubmed: 24360494
Mycopathologia. 2015 Apr;179(3-4):173-85
pubmed: 25547374
Assay Drug Dev Technol. 2018 Jul;16(5):232-246
pubmed: 29446984
Open Orthop J. 2016 Nov 30;10:615-632
pubmed: 28503214
Clin Orthop Relat Res. 2013 Sep;471(9):3002-9
pubmed: 23633184
Int Orthop. 2020 Jan;44(1):15-22
pubmed: 31254016
Clin Infect Dis. 1999 Aug;29(2):292-5
pubmed: 10476729
Acta Orthop. 2013 Dec;84(6):517-23
pubmed: 24171675
J Arthroplasty. 2012 Feb;27(2):293-8
pubmed: 21752583
J Rheumatol. 1983 Jun;10(3):494-5
pubmed: 6684169
Nat Rev Microbiol. 2018 Jan;16(1):19-31
pubmed: 29062072
J Bone Joint Surg Am. 2009 Nov;91 Suppl 6:142-9
pubmed: 19884422
Eur J Orthop Surg Traumatol. 2020 Feb;30(2):313-321
pubmed: 31578679
Knee. 2018 Aug;25(4):631-637
pubmed: 29778657
J Arthroplasty. 2018 Nov;33(11):3555-3560
pubmed: 30150154
Bone Joint J. 2019 May;101-B(5):589-595
pubmed: 31038988
JAMA. 2012 Sep 26;308(12):1227-36
pubmed: 23011713
J Infect. 2001 Jan;42(1):74-6
pubmed: 11243760
Mycopathologia. 2019 Feb;184(1):23-33
pubmed: 30051279
J Arthroplasty. 2004 Feb;19(2):248-52
pubmed: 14973873
J Arthroplasty. 2017 Aug;32(8):2523-2530
pubmed: 28478188